Evidence map›Paper›PMID 29954426›Full record

ArticleEpigenetics & chromatin2018

The pioneer factor activity of c-Myb involves recruitment of p300 and induction of histone acetylation followed by acetylation-induced chromatin dissociation.

Bettina M Fuglerud, Marit Ledsaak, Marie Rogne, Ragnhild Eskeland, Odd S Gabrielsen

Open access · goldAbstract read
In one paragraph

Article in Epigenetics & chromatin, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. HemaSphere · 2024
    Article
  8. Review
  9. Article
  10. Review
  11. Regulation of Chromatin Architecture by Transcription Factor Binding.bioRxiv : the preprint server for biology · 2023
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Bettina M FuglerudDepartment of Biosciences, University of Oslo, P.O. Box 1066, 0316, Blindern, Oslo, Norway.
Marit LedsaakDepartment of Biosciences, University of Oslo, P.O. Box 1066, 0316, Blindern, Oslo, Norway.
Marie RogneDepartment of Biosciences, University of Oslo, P.O. Box 1066, 0316, Blindern, Oslo, Norway.
Ragnhild EskelandDepartment of Biosciences, University of Oslo, P.O. Box 1066, 0316, Blindern, Oslo, Norway.
Odd S GabrielsenDepartment of Biosciences, University of Oslo, P.O. Box 1066, 0316, Blindern, Oslo, Norway. o.s.gabrielsen@ibv.uio.no.ORCID 0000-0002-5975-8815
University of Oslo · NO

Funding

Kreftforeningen (NO) 3485238-2013Norges Forskningsråd (NO) 240768Norges Forskningsråd (NO) 262652
6 · The paper itself

Abstract

backgroundThe concept of pioneer transcription factors is emerging as an essential part of the epigenetic regulation, taking place during cell development and differentiation. However, the precise molecular mechanism underlying pioneer factor activity remains poorly understood. We recently reported that the transcription factor c-Myb acts as a pioneer factor in haematopoiesis, and a point mutation in its DNA binding domain, D152V, is able to abrogate this function.

resultsHere, we show that specific histone modifications, including H3K27ac, prevent binding of c-Myb to histone tails, representing a novel effect of histone modifications, namely restricting binding of a pioneer factor to chromatin. Furthermore, we have taken advantage of the pioneer-defect D152V mutant to investigate mechanisms of c-Myb's pioneer factor activity. We show that c-Myb-dependent transcriptional activation of a gene in inaccessible chromatin relies on c-Myb binding to histones, as well as on c-Myb interacting with the histone acetyltransferase p300. ChIP assays show that both wild type and the D152V mutant of c-Myb bind to a selected target gene at its promoter and enhancer, but only wild-type c-Myb causes opening and activation of the locus. Enhancement of histone acetylation restores activation of the same gene in the absence of c-Myb, suggesting that facilitating histone acetylation is a crucial part of the pioneer factor function of c-Myb.

conclusionsWe suggest a pioneer factor model in which c-Myb binds to regions of closed chromatin and then recruits histone acetyltransferases. By binding to histones, c-Myb facilitates histone acetylation, acting as a cofactor for p300 at c-Myb bound sites. The resulting H3K27ac leads to chromatin opening and detachment of c-Myb from the acetylated chromatin. We propose that the latter phenomenon, acetylation-induced chromatin dissociation, represents a mechanism for controlling the dynamics of pioneer factor binding to chromatin.

Indexed as

AcetylationAnimalsCell LineChlorocebus aethiopsChromatinCOS CellsE1A-Associated p300 ProteinEpigenesis, GeneticHistonesHumansK562 CellsMutationProto-Oncogene Proteins c-mybTranscription, GeneticChromatinE1A-Associated p300 ProteinEP300 protein, humanHistonesProto-Oncogene Proteins c-myb

Identifiers

PMID29954426
PMCPMC6022509
OpenAlexW2810804581

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.